Nasdaq
華爾街日報Enrollment will begin in January 2026
Participants will be treated with buntanetap for 36 months
The study aims to enroll 500 patients
Read more at globenewswire.comAnnovis Announces Open-Label Extension Study for Parkinson's Disease Patients
Barchart·12/18/2025 15:35:00
語音播報
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.